-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 20, the reporter learned from China hepatitis prevention foundation that: for adults who have no antibody after hepatitis B vaccination, 60 micrograms of recombinant hepatitis B vaccine first developed in China has been approved and listed by the State Food and drug administration, realizing the full coverage of hepatitis B vaccination population Liang Xiaofeng, director of the immune planning center of the National Center for Disease Control and prevention, said that the 60 μ g recombinant hepatitis B vaccine has the effect of activating the human immune response, ensuring the safety of the unresponsive population aged 16 and above According to Professor Zhuang Hui, academician of Chinese Academy of engineering, high dose and low injection times are the development trend of hepatitis B vaccine in the world Compared with 10 μ g for children and 20 μ g for adults, 60 μ g recombinant hepatitis B vaccine only needs one injection, which can reduce the procedure, save time and improve the vaccination rate